Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031)2026
Description
Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Overview:
The Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
The Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Pulmonary Embolism – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
218 Pages
- PULMONARY EMBOLISM PIPELINE ANALYSIS
- • Pulmonary embolism is best described as the blockage of a pulmonary artery that travels to the lungs from other parts of the body by the formation of blood clots.
- • It is caused due to deep vein thrombosis that occurs due to inactivity and an injury. Some of the symptoms of pulmonary embolism include irregular heartbeat, cough, leg pain or swelling, excessive sweating, anxiety, chest pain, weak pulse, and confusion.
- • Predisposing factors include cardiovascular disease and high blood pressure. Around 80% of patients with pulmonary embolism have signs of deep vein thrombosis, and approximately 50% of patients with proven proximal deep vein thrombosis have an associated pulmonary embolism. Treatment includes anticoagulants and thrombolytics.
- • Immediate therapeutic anticoagulation is triggered for patients with suspected pulmonary embolism (PE) or deep venous thrombosis (DVT). XARELTO® is the only first and oral anticoagulant approved to treat DVT and PE.
- • Newly, FDA approved Savaysa (edoxaban), a Factor Xa inhibitor and worked as an anticoagulant is used in the treatment of deep vein thrombosis, pulmonary embolism and risk of embolism due to atrial fibrillation and stroke. Anticoagulation therapy with heparin has shown a reduction of mortality rates from 30% to less than 10%. Anticoagulation is essential, but anticoagulation alone does not guarantee a successful outcome.
- • Anticoagulant medications that are used in treating pulmonary embolism include warfarin (Coumadin), heparin (Hepariv-B), fondaparinux (Arixtra) and low-molecular-weight heparin (such as Lovenox or Dalteparin). The other drugs for treating pulmonary embolism includes Acenocoumarol (Nistrom), Danaparoid, Dextran (Rallidex), Dipyridamole (Persantin), Streptokinase (Thrombosolv), Urokinase (Dukinase). Only less number of studies are found in clinical trial development among which only 9 studies are going on in phase 3 trial of development including Edoxaban by Daiichi Sankyo, Furosemide, Dabigatran etexilate, Tinzaparin (Innohep), Apixaban and 4 studies in phase 2 clinical trial of development including Ateplase (Inderparin) by Tasly Pharmaceuticals, Enoxaparin, DS-1040b, and others.
- • Only 8 studies are found to be in early phase and phase 1 clinical trial development including TS23 Biological drug by Translational sciences, Ferumoxytol, and others.
- • The growth in the number of cancer patients, and an increase in per-capita healthcare expenditure, the aging population, etc. are expected to increase the pulmonary embolism diagnostic market. Yet the market faces some challenges, such as the prohibition of Technegas (an agent of V/Q Scan) in the US and introduction of Novel Oral Anticoagulants.
- • Globally, the rise in the awareness among people regarding existing treatments for pulmonary embolism, development of efficient and advanced technology, increasing government initiatives across the globe, growing prevalence and incidence rate of pulmonary embolism are the prime growth drivers of the pulmonary embolism treatment market.
- • However, higher cost of R&D, and entangled government regulatory approvals are the key restraints for the pulmonary embolism treatment market.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.